Objectives: Doxorubicin is a member of anthracycline antibiotic family that is widely used in the treatment of hematological malignances and solid tumors. The present study aimed to investigate the possible modulatory effects of labetalol on doxorubicin induced cardiotoxicity.
Materials and methods: Thirty Wale –Sprague male rats where used in this study. The animals were divided into three groups; Group 1 as the control, Group 2 received single dose of doxorubicin (15mg/kg) and Group 3 received labetalol (1mg/kg,po) daily for ten days and on 8th day, one hour after drug administration, a single dose of doxorubicin (15mg/kg) was given intraperitoneally.
Results: We observed an increase in cardiac biomarkers in the doxorubicin group compared to control group (LDH, MDA, Troponin I, interleukin-17), whereas pre-treatment with labetolol caused a decrease in cardiac biomarkers. Histopathalogical improvement in cardiac tissue was also observed.
Conclusion: Doxorubicin used as antineoplastic agent induces cardiotoxicity which limits its use. We concluded that labetalol produces differential effects and protection from doxorubicin induced cardiotoxicity via amelioration of cardiac biomarkers and histopathological changes.
doxorubicin; labetalol; cardiotoxicity